Disease burden of Barrett's esophagus across the Paris metropolitan area.

The prevalence of Barrett's esophagus (BE) in France is unknown. However, the management of dysplastic BE in expert centers is recommended and reduces the risk of developing invasive adenocarcinoma. Our aim was to determine the burden of BE patients in the Paris Region. We performed a retrospective study using the data from electronic medical records from the data warehouse of the 39 Greater Paris public hospitals (Entrepôt de données de santé de l' Assistance Publique- Hôpitaux de Paris) for the year 2018, and used natural language processing to search for occurrences of Barrett's esophagus in endoscopy and pathology reports. we observed a 2.2% prevalence of Barrett's esophagus. Patients with Barrett's esophagus were older, more frequently males, with a hiatal hernia, proton pump inhibitor users, and less frequently infected by H. Pylori. Gastro-esophageal reflux symptoms were not more frequently encountered in Barrett's patients. Eleven percent of patients with Barrett's esophagus had dysplasia or adenocarcinoma. Over 200 000 patients with Barrett's esophagus are expected in the Paris Region, of which 11% harbor dysplasia or adenocarcinoma. This data should be taken into account to tailor healthcare offer in France.

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest Maximilien Barret: Medtronic, Norgine, Olympus, Fujifilm, Pentax, Dr Falk Pharma, Sanofi Mathis Collier: none Viet-Thi Tran: none Mourad Delagi: none Nathanael Beeker: none